NASDAQ$TRVI

Trevi Therapeutics Inc · Q1 2026 earnings

Q1 2026 earnings ·

Headline financials

EPS (adj)

-$0.09

Previous: -$0.09+0.0%
Capital Expenditures

-$102K

No prior period
Net Income

-$13.2M

Previous: -$10.3M-27.6%

Revenue & EPS history

Trevi Therapeutics Inc · Revenue · Quarterly

$0

Q3 2025

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 11 quarterly earnings reports · overlaid with Q1 2026

Historical avgQ1 2026

+0.6%

Avg return

Earnings day

-1.3%

Avg return

5 days after

+9.7%

Avg return

30 days after

42%

5 / 12 earnings

Positive

+8.1%

Q2 2024

Best reaction

-4.5%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+1.9%+0.8%
Q4 2025-4.5%-3.8%+36.1%
Q3 2025-3.3%-4.6%+7.8%
Q1 2025-0.9%-3.1%+6.0%
Q3 2024+2.6%+1.7%-8.6%
Q2 2024+8.1%+4.2%+13.9%
Q1 2024-1.4%-7.1%-16.0%
Q3 2023+0.0%-6.0%-16.1%
Q2 2023+4.8%+3.5%+0.4%
Q1 2023+0.0%-2.2%+85.9%
Q3 2022+0.0%+14.0%+20.7%
Q2 2022+0.2%-13.1%-23.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro